View in EDS PDF Full Text

The anti-IgE mAb omalizumab induces adverse reactions by engaging Fcγ receptors.

Saved in:
Bibliographic Details
Title: The anti-IgE mAb omalizumab induces adverse reactions by engaging Fcγ receptors.
Authors: Balbino B; Unit of Antibodies in Therapy and Pathology, Institut Pasteur, UMR1222 INSERM, Paris, France.; Sorbonne Université, Paris, France., Herviou P; Unit of Antibodies in Therapy and Pathology, Institut Pasteur, UMR1222 INSERM, Paris, France., Godon O; Unit of Antibodies in Therapy and Pathology, Institut Pasteur, UMR1222 INSERM, Paris, France., Stackowicz J; Unit of Antibodies in Therapy and Pathology, Institut Pasteur, UMR1222 INSERM, Paris, France.; Sorbonne Université, Paris, France., Goff OR; Unit of Antibodies in Therapy and Pathology, Institut Pasteur, UMR1222 INSERM, Paris, France., Iannascoli B; Unit of Antibodies in Therapy and Pathology, Institut Pasteur, UMR1222 INSERM, Paris, France., Sterlin D; Unit of Antibodies in Therapy and Pathology, Institut Pasteur, UMR1222 INSERM, Paris, France.; Assistance Publique-Hôpitaux de Paris, La Pitié-Salpêtrière, Département d'Immunologie, Paris, France., Brûlé S; Plateforme de Biophysique Moléculaire, Institut Pasteur, UMR 3528 CNRS, Paris, France., Millot GA; Hub de Bioinformatique et Biostatistique, Département Biologie Computationnelle, Institut Pasteur, USR 3756 CNRS, Paris, France., Harris FM; Regeneron Pharmaceuticals Inc., Tarrytown, New York, USA., Voronina VA; Regeneron Pharmaceuticals Inc., Tarrytown, New York, USA., Nadeau KC; Sean N. Parker Center for Allergy and Asthma Research, Stanford University, Stanford, California, USA.; Division of Pulmonary and Critical Care, Department of Medicine, Stanford University, California, USA., Macdonald LE; Regeneron Pharmaceuticals Inc., Tarrytown, New York, USA., Murphy AJ; Regeneron Pharmaceuticals Inc., Tarrytown, New York, USA., Bruhns P; Unit of Antibodies in Therapy and Pathology, Institut Pasteur, UMR1222 INSERM, Paris, France., Reber LL; Unit of Antibodies in Therapy and Pathology, Institut Pasteur, UMR1222 INSERM, Paris, France.; Center for Physiopathology of Toulouse-Purpan (CPTP), UMR 1043, University of Toulouse, INSERM CNRS, Toulouse France.
Source: The Journal of clinical investigation [J Clin Invest] 2020 Mar 02; Vol. 130 (3), pp. 1330-1335.
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
Journal Info: Publisher: American Society for Clinical Investigation Country of Publication: United States NLM ID: 7802877 Publication Model: Print Cited Medium: Internet ISSN: 1558-8238 (Electronic) Linking ISSN: 00219738 NLM ISO Abbreviation: J Clin Invest Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Links:
  – Type: pdflink
Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 31770111
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: The anti-IgE mAb omalizumab induces adverse reactions by engaging Fcγ receptors.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Balbino+B%22">Balbino B</searchLink>; Unit of Antibodies in Therapy and Pathology, Institut Pasteur, UMR1222 INSERM, Paris, France.; Sorbonne Université, Paris, France.<br /><searchLink fieldCode="AU" term="%22Herviou+P%22">Herviou P</searchLink>; Unit of Antibodies in Therapy and Pathology, Institut Pasteur, UMR1222 INSERM, Paris, France.<br /><searchLink fieldCode="AU" term="%22Godon+O%22">Godon O</searchLink>; Unit of Antibodies in Therapy and Pathology, Institut Pasteur, UMR1222 INSERM, Paris, France.<br /><searchLink fieldCode="AU" term="%22Stackowicz+J%22">Stackowicz J</searchLink>; Unit of Antibodies in Therapy and Pathology, Institut Pasteur, UMR1222 INSERM, Paris, France.; Sorbonne Université, Paris, France.<br /><searchLink fieldCode="AU" term="%22Goff+OR%22">Goff OR</searchLink>; Unit of Antibodies in Therapy and Pathology, Institut Pasteur, UMR1222 INSERM, Paris, France.<br /><searchLink fieldCode="AU" term="%22Iannascoli+B%22">Iannascoli B</searchLink>; Unit of Antibodies in Therapy and Pathology, Institut Pasteur, UMR1222 INSERM, Paris, France.<br /><searchLink fieldCode="AU" term="%22Sterlin+D%22">Sterlin D</searchLink>; Unit of Antibodies in Therapy and Pathology, Institut Pasteur, UMR1222 INSERM, Paris, France.; Assistance Publique-Hôpitaux de Paris, La Pitié-Salpêtrière, Département d'Immunologie, Paris, France.<br /><searchLink fieldCode="AU" term="%22Brûlé+S%22">Brûlé S</searchLink>; Plateforme de Biophysique Moléculaire, Institut Pasteur, UMR 3528 CNRS, Paris, France.<br /><searchLink fieldCode="AU" term="%22Millot+GA%22">Millot GA</searchLink>; Hub de Bioinformatique et Biostatistique, Département Biologie Computationnelle, Institut Pasteur, USR 3756 CNRS, Paris, France.<br /><searchLink fieldCode="AU" term="%22Harris+FM%22">Harris FM</searchLink>; Regeneron Pharmaceuticals Inc., Tarrytown, New York, USA.<br /><searchLink fieldCode="AU" term="%22Voronina+VA%22">Voronina VA</searchLink>; Regeneron Pharmaceuticals Inc., Tarrytown, New York, USA.<br /><searchLink fieldCode="AU" term="%22Nadeau+KC%22">Nadeau KC</searchLink>; Sean N. Parker Center for Allergy and Asthma Research, Stanford University, Stanford, California, USA.; Division of Pulmonary and Critical Care, Department of Medicine, Stanford University, California, USA.<br /><searchLink fieldCode="AU" term="%22Macdonald+LE%22">Macdonald LE</searchLink>; Regeneron Pharmaceuticals Inc., Tarrytown, New York, USA.<br /><searchLink fieldCode="AU" term="%22Murphy+AJ%22">Murphy AJ</searchLink>; Regeneron Pharmaceuticals Inc., Tarrytown, New York, USA.<br /><searchLink fieldCode="AU" term="%22Bruhns+P%22">Bruhns P</searchLink>; Unit of Antibodies in Therapy and Pathology, Institut Pasteur, UMR1222 INSERM, Paris, France.<br /><searchLink fieldCode="AU" term="%22Reber+LL%22">Reber LL</searchLink>; Unit of Antibodies in Therapy and Pathology, Institut Pasteur, UMR1222 INSERM, Paris, France.; Center for Physiopathology of Toulouse-Purpan (CPTP), UMR 1043, University of Toulouse, INSERM CNRS, Toulouse France.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%227802877%22">The Journal of clinical investigation</searchLink> [J Clin Invest] 2020 Mar 02; Vol. 130 (3), pp. 1330-1335.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Research Support, Non-U.S. Gov't
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22American+Society+for+Clinical+Investigation%22">American Society for Clinical Investigation </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>7802877 <i>Publication Model: </i>Print <i>Cited Medium: </i>Internet <i>ISSN: </i>1558-8238 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2200219738%22">00219738 </searchLink><i>NLM ISO Abbreviation: </i>J Clin Invest <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=31770111
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1172/JCI129697
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 1330
    Titles:
      – TitleFull: The anti-IgE mAb omalizumab induces adverse reactions by engaging Fcγ receptors.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Balbino B
      – PersonEntity:
          Name:
            NameFull: Herviou P
      – PersonEntity:
          Name:
            NameFull: Godon O
      – PersonEntity:
          Name:
            NameFull: Stackowicz J
      – PersonEntity:
          Name:
            NameFull: Goff OR
      – PersonEntity:
          Name:
            NameFull: Iannascoli B
      – PersonEntity:
          Name:
            NameFull: Sterlin D
      – PersonEntity:
          Name:
            NameFull: Brûlé S
      – PersonEntity:
          Name:
            NameFull: Millot GA
      – PersonEntity:
          Name:
            NameFull: Harris FM
      – PersonEntity:
          Name:
            NameFull: Voronina VA
      – PersonEntity:
          Name:
            NameFull: Nadeau KC
      – PersonEntity:
          Name:
            NameFull: Macdonald LE
      – PersonEntity:
          Name:
            NameFull: Murphy AJ
      – PersonEntity:
          Name:
            NameFull: Bruhns P
      – PersonEntity:
          Name:
            NameFull: Reber LL
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 02
              M: 03
              Text: 2020 Mar 02
              Type: published
              Y: 2020
          Identifiers:
            – Type: issn-electronic
              Value: 1558-8238
          Numbering:
            – Type: volume
              Value: 130
            – Type: issue
              Value: 3
          Titles:
            – TitleFull: The Journal of clinical investigation
              Type: main
ResultId 1